Intellia Therapeutics (NTLA) Stock Price Down 6.1%
Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 6.1% on Tuesday . The company traded as low as $21.25 and last traded at $21.59. 749,500 shares changed hands during trading, an increase of 119% from the average session volume of 342,112 shares. The stock had previously closed at $23.00.
Several brokerages have recently commented on NTLA. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a report on Tuesday, August 29th. Barclays restated a “buy” rating on shares of Intellia Therapeutics in a research report on Sunday, November 5th. ValuEngine cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Jefferies Group reissued a “buy” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $30.17.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The business’s revenue was up 49.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.22) EPS. equities research analysts predict that Intellia Therapeutics Inc will post -1.68 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 10.2% during the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares during the period. GMT Capital Corp acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $8,214,000. Granahan Investment Management Inc. MA boosted its position in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after acquiring an additional 18,784 shares in the last quarter. Ark Investment Management LLC boosted its position in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after acquiring an additional 94,960 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after acquiring an additional 56,363 shares in the last quarter. 49.53% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.